The Europe Benign Prostatic Hyperplasia Therapeutics Market would witness market growth of 3.9% CAGR during the forecast period (2021-2027).
BPH is neither a malignancy nor a cause of prostate cancer. BPH, on the other hand, can be inconvenient and, in a number of instances, can lead to bladder obstruction. It appears to be a natural part of the aging process, affecting men over the age of 40. Benign prostate hyperplasia is characterized by the presence of discrete nodules in the periurethral zone of the prostate gland.
To treat BPH symptoms, drugs such as alpha-blockers, 5-alpha reductase inhibitors, and phosphodiesterase-5 inhibitors are employed. These treatments relax the smooth bladder muscles or reduce the abnormal prostate growth. The prostate's grasp on the urethra loosens as bladder muscles relax, enabling urine to flow more freely. Prostate shrinking, on the other hand, lessens the pressure produced by the prostate on the urethra, allowing urine to flow freely.
Despite the fact that 40% of men over the age of 60 have an enlarged prostate, a new poll published by the European Association of Urology (EAU) has shown that awareness of prostate health is disturbingly low among men over 50. Only 38% of respondents correctly identified the disease (beneficial prostate enlargement (BPE) or hyperplasia (BPH)). The main purpose of a healthy prostate, which is around the size of a walnut, is to produce prostatic fluid, which is used to transport sperm. Despite the fact that it grows slowly as men age, just one in six (17%) respondents correctly said that symptoms associated with an enlarged prostate are not a "typical" indicator of aging.
The Germany market dominated the Europe Benign Prostatic Hyperplasia Therapeutics Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $481.1 million by 2027. The UK market would experience a CAGR of 3.1% during (2021 - 2027). Additionally, The France market is anticipated to grow a CAGR of 4.6% during (2021 - 2027).
Based on Therapy, the market is segmented into Mono Drug Therapy and Combination Drug Therapy. Based on Therapeutics Class, the market is segmented into Alpha Blockers, 5- alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Benign Prostatic Hyperplasia Therapeutics Market Size will Hit $7.4 Billion by 2027, at a CAGR of 4.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Mono Drug Therapy
- Combination Drug Therapy
By Therapeutics Class
- Alpha Blockers
- 5- alpha Reductase Inhibitors
- Phosphodiesterase-5 Inhibitors
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC (GSK)
- Astellas Pharma, Inc.
- Eli Lilly and Company
- Allergan PLC (AbbVie)
- Merck Group (Merck Sharp & Dohme Corp.)
- Boehringer Ingelheim International GmbH
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Pfizer, Inc.
- Abbott Laboratories
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Benign Prostatic Hyperplasia Therapeutics Market, by Therapy
1.4.2 Europe Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class
1.4.3 Europe Benign Prostatic Hyperplasia Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy
3.1 Europe Mono Drug Therapy Market by Country
3.2 Europe Combination Drug Therapy Market by Country
Chapter 4. Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
4.1 Europe Alpha Blockers Market by Country
4.2 Europe 5- alpha Reductase Inhibitors Market by Country
4.3 Europe Phosphodiesterase-5 Inhibitors Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe Benign Prostatic Hyperplasia Therapeutics Market by Country
5.1 Germany Benign Prostatic Hyperplasia Therapeutics Market
5.1.1 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.2 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2 UK Benign Prostatic Hyperplasia Therapeutics Market
5.2.1 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.2 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3 France Benign Prostatic Hyperplasia Therapeutics Market
5.3.1 France Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.2 France Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4 Russia Benign Prostatic Hyperplasia Therapeutics Market
5.4.1 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.2 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.5 Spain Benign Prostatic Hyperplasia Therapeutics Market
5.5.1 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.5.2 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.6 Italy Benign Prostatic Hyperplasia Therapeutics Market
5.6.1 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.6.2 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.7 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market
5.7.1 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.7.2 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
Chapter 6. Company Profiles
6.1 GlaxoSmithKline PLC (GSK)
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Astellas Pharma, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expense
6.3 Eli Lilly and Company
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expense
6.4 Allergan PLC (AbbVie)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.5 Merck Group (Merck Sharp & Dohme Corp.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Boehringer Ingelheim International Gmbh
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional & Segmental Analysis
6.6.4 Research & Development Expenses
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expenses
6.8 Sanofi S.A.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Abbott Laboratories
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
TABLE 1 Europe Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 2 Europe Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 3 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 4 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 5 Europe Mono Drug Therapy Market by Country, 2017 - 2020, USD Million
TABLE 6 Europe Mono Drug Therapy Market by Country, 2021 - 2027, USD Million
TABLE 7 Europe Combination Drug Therapy Market by Country, 2017 - 2020, USD Million
TABLE 8 Europe Combination Drug Therapy Market by Country, 2021 - 2027, USD Million
TABLE 9 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 10 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 11 Europe Alpha Blockers Market by Country, 2017 - 2020, USD Million
TABLE 12 Europe Alpha Blockers Market by Country, 2021 - 2027, USD Million
TABLE 13 Europe 5- alpha Reductase Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 14 Europe 5- alpha Reductase Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 15 Europe Phosphodiesterase-5 Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 16 Europe Phosphodiesterase-5 Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 17 Europe Others Market by Country, 2017 - 2020, USD Million
TABLE 18 Europe Others Market by Country, 2021 - 2027, USD Million
TABLE 19 Europe Benign Prostatic Hyperplasia Therapeutics Market by Country, 2017 - 2020, USD Million
TABLE 20 Europe Benign Prostatic Hyperplasia Therapeutics Market by Country, 2021 - 2027, USD Million
TABLE 21 Germany Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 22 Germany Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 23 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 24 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 25 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 26 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 27 UK Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 28 UK Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 29 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 30 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 31 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 32 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 33 France Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 34 France Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 35 France Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 36 France Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 37 France Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 38 France Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 39 Russia Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 40 Russia Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 41 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 42 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 43 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 44 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 45 Spain Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 46 Spain Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 47 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 48 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 49 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 50 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 51 Italy Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 52 Italy Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 53 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 54 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 55 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 56 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 57 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 58 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 59 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 60 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 61 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 62 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 63 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 64 key information – Astellas Pharma, Inc.
TABLE 65 Key Information – Eli Lilly and Company
TABLE 66 Key Information – Allergan PLC
TABLE 67 key Information – Merck Group
TABLE 68 Key Information – Boehringer Ingelheim International GmbH
TABLE 69 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 70 Key Information – Sanofi S.A.
TABLE 71 Key Information – Pfizer, Inc.
TABLE 72 Key Information – Abbott Laboratories
List of Figures
FIG 1 Methodology for the research